Noriko Mitome
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Noriko Mitome has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Haruhiko Fukuda
9 shared publicationsKeiju Aokage
8 shared publicationsMasashi Wakabayashi
5 shared publicationsShun-Ichi Watanabe
5 shared publications- Haruhiko Fukuda
Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
4 shared publications Masaya Yotsukura
4 shared publications
Latest Publications
- 10 November 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 53  (1)
Zone-specific lymph node metastasis prediction model in clinical stage IâII non-small cell lung cancer: a supplementary analysis of JCOG1413
- 10 November 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 53  (1)
Zone-specific lymph node metastasis prediction model in clinical stage IâII non-small cell lung cancer: a supplementary analysis of JCOG1413
- Open Access
- 24 September 2026
- Published by Elsevier in SSRN Electronic Journal
Lobectomy versus segmentectomy for centrally located, small-sized (⤠2 cm), and radiologically solid-dominant non-small cell lung cancer: a phase III randomized controlled trial (UNLIMITED; JCOG2501)
BackgroundSegmentectomy has demonstrated favorable long-term outcomes compared with lobectomy in patients with small peripheral non-small cell lung cancer (NSCLC). However, whether similar benefits can be achieved in centrally located, small-sized, radiologically solid-dominant NSCLC remains uncertain. This study aims to confirm the non-inferiority of segmentectomy to lobectomy within this setting.MethodsJCOG2501 is a multi-institutional, open-label, phase III, randomized controlled trial designed to confirm the non-inferiority of segmentectomy to lobectomy in patients with centrally located (within the inner two-thirds of the lung field), small-sized (maximum tumor diameter â¤2 cm), radiologically solid-dominant (consolidation-to-tumor ratio, >0.5 to â¤1) NSCLC. Eligible patients are aged 18â85 years with an Eastern Cooperative Oncology Group performance status of 0â1 and adequate pulmonary function. A two-step registration system is adopted, with preoperative and intraoperative confirmation of patient eligibility. Following confirmation of eligibility at the second registration, patients are randomized 1:1 to either the lobectomy or segmentectomy arm. In both arms, systematic or lobe-specific lymph node dissection is mandatory, and nodal sampling alone is prohibited. The primary endpoint is overall survival, analyzed in all randomized patients. Assuming a non-inferiority margin of 6.5% for 5-year overall survival, 490 patients are required to achieve 70% power with a one-sided Îą = 5%. The planned sample size is 500 patients at the second registration. JCOG2501 was initiated in February 2026 and is registered with the Japan Registry of Clinical Trials (jRCT1030250727).ConclusionsJCOG2501 will clarify the role of segmentectomy in centrally located small-sized NSCLC and inform future surgical standards.
- 24 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLobectomy versus segmentectomy for centrally located, small-sized (⤠2 cm), and radiologically solid-dominant non-small cell lung cancer: a phase III randomized controlled trial (UNLIMITED; JCOG2501)
BackgroundSegmentectomy has demonstrated favorable long-term outcomes compared with lobectomy in patients with small peripheral non-small cell lung cancer (NSCLC). However, whether similar benefits can be achieved in centrally located, small-sized, radiologically solid-dominant NSCLC remains uncertain. This study aims to confirm the non-inferiority of segmentectomy to lobectomy within this setting.MethodsJCOG2501 is a multi-institutional, open-label, phase III, randomized controlled trial designed to confirm the non-inferiority of segmentectomy to lobectomy in patients with centrally located (within the inner two-thirds of the lung field), small-sized (maximum tumor diameter â¤2 cm), radiologically solid-dominant (consolidation-to-tumor ratio, >0.5 to â¤1) NSCLC. Eligible patients are aged 18â85 years with an Eastern Cooperative Oncology Group performance status of 0â1 and adequate pulmonary function. A two-step registration system is adopted, with preoperative and intraoperative confirmation of patient eligibility. Following confirmation of eligibility at the second registration, patients are randomized 1:1 to either the lobectomy or segmentectomy arm. In both arms, systematic or lobe-specific lymph node dissection is mandatory, and nodal sampling alone is prohibited. The primary endpoint is overall survival, analyzed in all randomized patients. Assuming a non-inferiority margin of 6.5% for 5-year overall survival, 490 patients are required to achieve 70% power with a one-sided Îą = 5%. The planned sample size is 500 patients at the second registration. JCOG2501 was initiated in February 2026 and is registered with the Japan Registry of Clinical Trials (jRCT1030250727).ConclusionsJCOG2501 will clarify the role of segmentectomy in centrally located small-sized NSCLC and inform future surgical standards.
- Open Access
- 20 August 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27  (8) , 54-58
A Multicenter Randomized Phase III Trial Comparing MET Tyrosine Kinase Inhibitors vs. Immune Checkpoint Inhibitors With or Without Chemotherapy as First-Line Treatment for Patients With Advanced NonâSmall Cell Lung Cancer Harboring MET Exon 14 Skipping Mutations: JCOG2506 (DECIDE-MET)
- 20 August 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27  (8) , 54-58
Open AccessA Multicenter Randomized Phase III Trial Comparing MET Tyrosine Kinase Inhibitors vs. Immune Checkpoint Inhibitors With or Without Chemotherapy as First-Line Treatment for Patients With Advanced NonâSmall Cell Lung Cancer Harboring MET Exon 14 Skipping Mutations: JCOG2506 (DECIDE-MET)
- 3 August 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56  (11) , 1450-1454
A single-arm phase III trial evaluating the non-inferiority of less-intensive surveillance for early gastric cancer: JCOG2504 (less-surveillance EGC)
Patients with pathological stage I (pStage I) gastric cancer (GC) have a very low recurrence risk after curative resection. Nevertheless, intensive postoperative surveillance, similar to that for advanced disease, is widely practiced despite the unclear survival benefit. Previous studies have not demonstrated improved overall survival (OS) through early detection of asymptomatic recurrence; however, intensive surveillance may cause unnecessary radiation exposure, patient burdens, and increased healthcare costs. Therefore, evidence is needed to determine whether a less-intensive risk-adapted surveillance strategy is clinically acceptable for this low-risk population. We designed a single-arm phase III trial (JCOG2504) to confirm the non-inferiority of less-intensive surveillance compared to standard surveillance in patients with pStage I GC after curative resection. The primary endpoint is OS. A total of 605 patients from 66 institutions will be enrolled over 3 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCT1030250844).
- 3 August 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56  (11) , 1450-1454
A single-arm phase III trial evaluating the non-inferiority of less-intensive surveillance for early gastric cancer: JCOG2504 (less-surveillance EGC)
Patients with pathological stage I (pStage I) gastric cancer (GC) have a very low recurrence risk after curative resection. Nevertheless, intensive postoperative surveillance, similar to that for advanced disease, is widely practiced despite the unclear survival benefit. Previous studies have not demonstrated improved overall survival (OS) through early detection of asymptomatic recurrence; however, intensive surveillance may cause unnecessary radiation exposure, patient burdens, and increased healthcare costs. Therefore, evidence is needed to determine whether a less-intensive risk-adapted surveillance strategy is clinically acceptable for this low-risk population. We designed a single-arm phase III trial (JCOG2504) to confirm the non-inferiority of less-intensive surveillance compared to standard surveillance in patients with pStage I GC after curative resection. The primary endpoint is OS. A total of 605 patients from 66 institutions will be enrolled over 3 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCT1030250844).
- Open Access
- 7 July 2026
- Published by Elsevier in SSRN Electronic Journal
A multicenter randomized phase III trial comparing MET tyrosine kinase inhibitors versus immune checkpoint inhibitors with or without chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer harboring MET exon 14 skipping mutations: JCOG2506 (DECIDE-MET)
- 7 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA multicenter randomized phase III trial comparing MET tyrosine kinase inhibitors versus immune checkpoint inhibitors with or without chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer harboring MET exon 14 skipping mutations: JCOG2506 (DECIDE-MET)
- Open Access
- 6 July 2026
- Published by Elsevier in Lung Cancer
- Vol. 219, 109520
Adjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206
- 6 July 2026
- Published by Elsevier in Lung Cancer
- Vol. 219, 109520
Open AccessAdjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206
- Open Access
- 18 June 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56  (9) , 1145-1151
A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART)
Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy. Patients refractory to high-dose methotrexateâbased induction therapy have an extremely poor prognosis. Although whole-brain radiotherapy (WBRT) is the standard salvage treatment and provides potent tumor control, early functional deterioration and late neurocognitive toxicity remain major concerns. A phase I/II trial on relapsed or refractory PCNSL demonstrated favorable efficacy and tolerability of tirabrutinib, a second-generation selective Brutonâs tyrosine kinase inhibitor. Tirabrutinibâs oral administration has enabled outpatient management. However, its clinical value for induction-refractory PCNSL remains uncertain. We designed a multicenter, randomized phase II/III trial (JCOG2314) to assess the non-inferiority of tirabrutinib to WBRT in overall survival and its potential to reduce functional deterioration and cognitive impairment. A total of 94 patients from 49 institutions will be enrolled over 4 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCT1031250645).
- 18 June 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56  (9) , 1145-1151
Open AccessA multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART)
Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy. Patients refractory to high-dose methotrexateâbased induction therapy have an extremely poor prognosis. Although whole-brain radiotherapy (WBRT) is the standard salvage treatment and provides potent tumor control, early functional deterioration and late neurocognitive toxicity remain major concerns. A phase I/II trial on relapsed or refractory PCNSL demonstrated favorable efficacy and tolerability of tirabrutinib, a second-generation selective Brutonâs tyrosine kinase inhibitor. Tirabrutinibâs oral administration has enabled outpatient management. However, its clinical value for induction-refractory PCNSL remains uncertain. We designed a multicenter, randomized phase II/III trial (JCOG2314) to assess the non-inferiority of tirabrutinib to WBRT in overall survival and its potential to reduce functional deterioration and cognitive impairment. A total of 94 patients from 49 institutions will be enrolled over 4 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCT1031250645).
- Open Access
- 4 June 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68  (6)
Oncologic Safety of Omitting Mediastinal Lymph Node Dissection in Segmentectomy for Ground-Glass Opacity-Dominant Lung Cancer: A Supplementary Analysis of JCOG1211
- 4 June 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68  (6)
Open AccessOncologic Safety of Omitting Mediastinal Lymph Node Dissection in Segmentectomy for Ground-Glass Opacity-Dominant Lung Cancer: A Supplementary Analysis of JCOG1211
- Open Access
- 22 April 2026
- Published by Elsevier in SSRN Electronic Journal
Adjuvant Chemotherapy Intensity and Prognosis in Completely Resected High-Grade Neuroendocrine Lung Carcinoma: A Post Hoc Analysis of JCOG1205/1206
Highlights Increasing adjuvant chemotherapy intensity did not improve prognosis in HGNEC.Completion of adjuvant chemotherapy did not improve RFS or OS.High relative dose intensity did not associate with RFS in EP or IP regimens.Routine pursuit of high-dose intensity may be unnecessary.
- 22 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAdjuvant Chemotherapy Intensity and Prognosis in Completely Resected High-Grade Neuroendocrine Lung Carcinoma: A Post Hoc Analysis of JCOG1205/1206
Highlights Increasing adjuvant chemotherapy intensity did not improve prognosis in HGNEC.Completion of adjuvant chemotherapy did not improve RFS or OS.High relative dose intensity did not associate with RFS in EP or IP regimens.Routine pursuit of high-dose intensity may be unnecessary.
- 13 April 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27  (5) , 5-10
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)
- 13 April 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27  (5) , 5-10
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)